{"altmetric_id":16653224,"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["Andres J. M. Ferreri, IRCCS San Raffaele"],"first_seen_on":"2017-02-22T15:29:57+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1487775600,"links":["https:\/\/clinicaltrials.gov\/show\/NCT00799513"],"nct_id":"NCT00799513","pubdate":"2008-11-20T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma","type":"clinical_trial_study_record"},"altmetric_score":{"score":7,"score_history":{"1y":7,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":7},"context_for_score":{"all":{"total_number_of_other_articles":8255097,"mean":6.9732502228862,"rank":1199969,"this_scored_higher_than_pct":84,"this_scored_higher_than":6980704,"rank_type":"exact","sample_size":8255097,"percentile":84},"similar_age_3m":{"total_number_of_other_articles":242694,"mean":13.702869246331,"rank":55275,"this_scored_higher_than_pct":76,"this_scored_higher_than":184573,"rank_type":"exact","sample_size":242694,"percentile":76},"this_journal":{"total_number_of_other_articles":23859,"mean":10.38323673401,"rank":3994,"this_scored_higher_than_pct":75,"this_scored_higher_than":17966,"rank_type":"exact","sample_size":23859,"percentile":75},"similar_age_this_journal_3m":{"total_number_of_other_articles":772,"mean":12.947675745785,"rank":86,"this_scored_higher_than_pct":84,"this_scored_higher_than":656,"rank_type":"exact","sample_size":772,"percentile":84}}},"demographics":[],"counts":{"total":{"posts_count":2},"news":{"unique_users_count":1,"unique_users":["oncology_nurse_advisor"],"posts_count":2}},"posts":{"news":[{"title":"Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL","url":"http:\/\/www.oncologynurseadvisor.com\/lenalidomide-active-as-maintenance-therapy-in-patients-with-relapsed-dlbcl\/article\/639491\/","license":"public","citation_ids":[16653224,16491975],"posted_on":"2017-02-22T15:00:00+00:00","summary":"February 22, 2017 Single-agent maintenance after salvage therapy might be a promising approach to aid patients with relapsed DLBCL not eligible for autologous HCT.","author":{"name":"Oncology Nurse Advisor ","url":"http:\/\/www.oncologynurseadvisor.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/276\/normal\/Screen_Shot_2014-11-20_at_11.19.42.png?1416482413"}},{"title":"Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL","url":"http:\/\/ct.moreover.com\/?a=29674941546&p=1pl&v=1&x=T1ReJi54fNhMyRd0KmskpA","license":"public","citation_ids":[16653224,16491975],"posted_on":"2017-02-22T15:00:00+00:00","summary":"February 22, 2017 Single-agent maintenance after salvage therapy might be a promising approach to aid patients with relapsed DLBCL not eligible for autologous HCT.","author":{"name":"Oncology Nurse Advisor ","url":"http:\/\/www.oncologynurseadvisor.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/276\/normal\/Screen_Shot_2014-11-20_at_11.19.42.png?1416482413"}}]}}